Clinical trials: Major Depressive Episode
Bipolar I Disorder
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo).
- Trial name
- Illuminate1 (NCT07494305)
- Testing
- LB-102
- Where
- 26 sites in United States
- Volunteers
- 320 people
- Sponsor
- LB Pharmaceuticals Inc.
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Depressive Disorder, Major
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD- 2 (NCT07775300)
- Testing
- Brenipatide
- Where
- 170 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Depressive Episode, Depressive Disorder
Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics.
The investigators will perform a double-blind, randomized, sham-controlled clinical trial of theta-burst stimulation (TBS) in mixed depressive episodes of both bipolar and major depressive disorders.
- Conditions
- Depressive Episode, Depressive Disorder, Bipolar Disorder
- Trial name
- NCT04123301
- Testing
- Active Theta Burst Stimulation (TBS)
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- University of Sao Paulo
Major Depressive Disorders
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive…
- Trial name
- NCT00825019
- Testing
- amibegron (SR58611A), paroxetine
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- Sanofi
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Depression / Major Depressive Disorder
Augmented Depression Therapy (ADepT) Case Series
This research study plans to examine the use of Augmented Depression Therapy (ADepT) in order to evaluate what patients think about ADepT and how well it works.
- Trial name
- NCT07733310
- Testing
- Augmented Depression Therapy (ADepT)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University
Major Depressive Episode
Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients
Unipolar major depressive disorder is the leading cause of disability worldwide. The most commonly used treatments for major depressive episodes (MDE) are antidepressant medications.
- Trial name
- MOODBOOSTER (NCT06508710)
- Testing
- Ketamine
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Episode
A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes
Patients with depression are acutely distressed, often suicidal, and unable to meet the demands of everyday life. If proven effective in a rigorously conducted multicenter randomized controlled trial (RCT), oral ketamine would…
- Trial name
- KOMET (NCT07839338)
- Testing
- Oral ketamine, Oral midazolam
- Where
- 5 sites in India
- Volunteers
- 220 people
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
Major Depressive Disorder
Effective of Transcranial Magnetic Stimulation (TMS) vs Treatment as Usual for First-Episode Depression in Adults
This clinical trial aims to assess the effectiveness of Transcranial Magnetic Stimulation (TMS) compared to Treatment as Usual (TAU) in adult patients experiencing their first or second episode of unipolar major depressive…
- Trial name
- NCT06644833
- Testing
- Transcranial magnetic stimulation, Antidepressant
- Volunteers
- 120 people
- Sponsor
- Sultan Qaboos University
Major Depressive Episode, Inflammatory Bowel Diseases
Microglial Activation in Inflammatory Bowel Disease
The purpose of this study is to monitor microglial activation in participants with inflammatory bowel disease (IBD) and investigate the relationship that exists between these patients and their risk of acquiring major depressive…
- Trial name
- NCT03487926
- Testing
- [18F]FEPPA
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Wellness Monitoring for Major Depressive Disorder
The Wellness Monitoring for Major Depressive Disorder (MDD) study is a prospective, longitudinal, observational study aimed at identifying biomarkers of relapse in MDD.
- Trial name
- CBN-Well (NCT02934334)
- Testing
- Observational
- Where
- 5 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Sidney Kennedy
Major Depressive Disorder
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode.
- Trial name
- NCT01684163
- Testing
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg
- Where
- 26 sites in United States
- Volunteers
- 369 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Bipolar Affective Disorder
Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.
Initially, observational studies suggested a possible effect of Lacosamide on depressive and anxious symptoms in individuals with epilepsy, and later, an open-label study demonstrated the efficacy of lacosamide in improving…
- Trial name
- NCT07412132
- Testing
- Lacosamide
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Major Depression, Depressive Episodes
Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health
The purpose of this randomized multiple-site clinical study is to determine whether a revised CATCH-IT (Internet-based depression prevention program) is more effective than a general health education Internet intervention (Health…
- Trial name
- CATCH-IT (NCT01893749)
- Testing
- CATCH-IT
- Where
- 7 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Benjamin Van Voorhees, MD, MPH
Major Depressive Disorder, Bipolar I and Bipolar II
Bipolar Proteomic Assay Validation Study
The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.
- Trial name
- NCT02746367
- Testing
- Diagnostic test (LDT)
- Where
- 5 sites in United States
- Volunteers
- 261 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Depression Chronic, Depression and Quality of Life
Remote Medical Monitoring of Patients With Depression
The goal of this clinical trial is to learn if ThIA Suivi, a digital tool for remote monitoring of patients, can improve the care of adults with depression who are followed by a psychiatrist.
- Conditions
- Depression Chronic, Depression and Quality of Life, Depression, Major Depressive Episode
- Trial name
- TELEMED-DEP (NCT07878754)
- Testing
- Use of ThIA Medical Device
- Where
- 3 sites in France
- Volunteers
- 608 people
- Sponsor
- ThIA Santé Mentale
Bipolar Disorder, Elderly
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
- Trial name
- NCT01737268
- Testing
- FK949E
- Where
- 32 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Creatine as a New Therapeutic Strategy in Depression
Creatine as a new therapeutic strategy in depression: A double-blind, parallel, randomized, add-on clinical trial of creatine versus placebo added to antidepressant treatment of patients with major depressive episode.
- Trial name
- NCT00313417
- Testing
- Creatine monohydrate
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Herzog Hospital